Cyclosporine nephrotoxicity
Cyclosporine nephrotoxicity
复制标题
DOI：
10.1016/j.transproceed.2004.01.021
复制
发表时间：
2004-03-01
影响因子：
0.9
通讯作者：
van der Woude, FJ
中科院分区：
文献类型：
--
作者：
Busauschina, A;Schnuelle, P;van der Woude, FJ
环孢素（CsA）是目前预防实体器官移植排斥反应的主要免疫抑制剂。然而，由于其分子作用机制，该药物与各种不良副作用（如肾毒性）有关。组织学变化表现为闭塞性血管病变的传入小动脉和肾小管间质纤维化的进展情况。这种疾病的潜在病理机制反映了血管活性物质（如血管紧张素II、内皮素、肾上腺素和一氧化氮）释放的改变，以及增殖基因（如转化生长因子-β、骨桥蛋白和胶原蛋白I和IV）的刺激。预防肾毒性的潜在策略进行了讨论。
Cyclosporine (CsA) is the current primary immunosuppressant for the prevention of allograft rejection in solid organ transplantation. However, owing to its molecular mechanism of action the drug is associated with various adverse side effects (eg, nephrotoxicity). Histological changes appear as obliterative vasculopathy of the afferent arteriole and tubulointerstitial fibrosis in advanced cases. The underlying pathomechanisms of this condition reflect an altered release of vasoactive substances, such as angiotensin II, endothelin, prostaglandins, and nitric oxide as well as the stimulation of proliferative genes such as transforming growth factor-beta, osteopontin, and collagen I and IV. Potential strategies for the prevention of nephrotoxicity are discussed.